EVVIVA® products are tested to predict their bioavailability in the intestinal tract responsible for absorption with an in vitro method which consists of 3 enzymatic incubation steps.
The table shows how much active substance remains unabsorbed during the different stages of digestion, comparing EVVIVA® FULL OMEGA 3 (Microencapsulated) to a similar product protected with another system.
In phase T3, only 1.5% of the active substance in EVVIVA® FULL OMEGA 3 remains undigested while the rest was properly absorbed in the intestine. With other protection systems, up to 49% of active substance remains unabsorbed.
|STEP||Conc.% Of undigested active substance EVVIVA® FULL OMEGA 3 | Microencapsulated||Conc.% Of active substance UNDIGESTED | protected with other technologies|